What precautions are needed for dental procedures and surgery in a patient with osteoporosis receiving zoledronic acid (Reclast)?

Precautions for Dental and Surgical Procedures in Patients on Reclast (Zoledronic Acid)

Patients on Reclast require comprehensive dental evaluation before starting therapy, meticulous oral hygiene during treatment, and should avoid invasive dental procedures while on therapy—if invasive dental work is necessary, defer Reclast until complete healing is confirmed by the dentist. 1, 2

Pre-Treatment Dental Assessment

Before initiating Reclast therapy:

• Obtain a comprehensive dental examination including evaluation of hard and soft tissues, periodontal assessment, and oral radiographs when feasible 3, 2
• Complete all necessary invasive dental procedures (extractions, implants, periodontal surgery) before starting bisphosphonate therapy and allow adequate healing time 4, 5
• Address all active oral infections and eliminate sites at high risk for infection 3

This pre-treatment approach is critical because the risk of medication-related osteonecrosis of the jaw (MRONJ) increases with invasive dental procedures performed during active therapy.

Risk of Osteonecrosis of the Jaw (MRONJ)

The absolute risk of MRONJ in osteoporosis patients on bisphosphonates is relatively low but real:

• General osteoporosis population: 0.001% to 0.01% (1 in 10,000 to 1 in 100,000) 4
• Long-term therapy (>4 years): up to 0.21% (21 in 10,000) 4
• Tooth extraction during therapy: 0.5% risk of developing MRONJ 4
• Reclast specifically: 1%-2% incidence reported in higher-dose oncology settings 1

Important caveat: Most patients who develop MRONJ have pre-existing dental problems, though not all 1. The risk is substantially higher in oncology patients receiving more frequent, higher doses compared to annual osteoporosis dosing.

During Active Reclast Therapy

Dental Care Guidelines

• Maintain excellent oral hygiene with routine dental care and regular check-ups (every 6 months recommended) 1, 4, 1, 3
• Avoid elective invasive dental procedures including non-medically necessary extractions, alveoloplasties, and implants 3
• Routine dental care is safe: cleanings, fillings, and non-surgical procedures can proceed normally 4

If Invasive Dental Surgery Becomes Necessary

There is conflicting guidance on drug holidays, reflecting genuine uncertainty in the evidence:

Option 1 - American Dental Association approach 4:

• Does NOT recommend stopping bisphosphonates for dental procedures
• If tooth extraction or implant is planned, consider deferring initiation of therapy until the area has healed

Option 2 - American Association of Oral and Maxillofacial Surgeons approach 4:

• Recommends a 2-month drug holiday for patients who have taken bisphosphonates for >4 years before invasive procedures

Option 3 - NCCN/Oncology consensus 1:

• Defer Reclast therapy until complete healing is confirmed by the dentist after invasive dental surgery
• This is the most conservative approach

My recommendation: Given that Reclast has prolonged skeletal effects lasting months to years after a single infusion, and that the next annual dose can be safely delayed, defer the next scheduled Reclast infusion if invasive dental work is planned or ongoing until the dentist confirms complete mucosal healing (typically 6-8 weeks). This approach balances fracture risk against MRONJ risk. 1, 3

Surgical Technique Considerations

If dental extraction must be performed during therapy:

• Consider alveolectomy (removal of alveolar bone) along with extraction 6
• Use appropriate antimicrobial prophylaxis (antibiotics and antimicrobial mouth rinse) 6
• Follow-up systematically every 6-8 weeks until full mucosal coverage achieved 3
• Some evidence suggests plasma rich in growth factors (PRGF) may reduce MRONJ risk, though this is not standard practice 7

For General Surgery (Non-Dental)

The FDA label and guidelines do not recommend stopping Reclast for general surgical procedures 2. The primary concerns are:

Pre-Operative Assessment

• Check renal function: Measure serum creatinine and calculate creatinine clearance before each dose 2
• Assess calcium status: Measure serum calcium; correct hypocalcemia before surgery 2
• Ensure adequate hydration: Patient should drink at least 2 glasses of fluid before infusion 2

Post-Operative Monitoring

• Calcium supplementation: Ensure adequate calcium (1200-1500 mg daily in divided doses) and vitamin D (800-1000 IU daily), especially in the 2 weeks following Reclast administration 1, 2
• Monitor for hypocalcemia: Particularly important in patients with history of parathyroid/thyroid surgery, malabsorption, or renal impairment 2

Key Risk Factors to Address

Modifiable risk factors that increase MRONJ risk 3:

• Poor oral health
• Ill-fitting dentures
• Uncontrolled diabetes mellitus
• Tobacco use
• Concomitant corticosteroid use
• Immunosuppression

Address these factors proactively with the multidisciplinary team.

Common Pitfall to Avoid

Do not assume a single annual dose of Reclast carries the same MRONJ risk as high-dose oncology regimens. While cases have been reported with annual Reclast for osteoporosis 8, 9, the absolute risk is substantially lower than with monthly oncology dosing. However, the risk is not zero, particularly in patients with prior long-term oral bisphosphonate use who transition to Reclast 9.

Patient Education Points

Inform patients to:

• Report any oral symptoms immediately (non-healing sores, exposed bone, pain, swelling) 2
• Inform their dentist they are taking Reclast before any dental work 5
• Maintain excellent oral hygiene throughout treatment 1, 2
• Report thigh or groin pain (atypical femur fracture risk, though rare) 2